Phase II clinical success of 0.25% Reproxalap eye drops marks a new breakthrough in the treatment of dry eye disease

Recently, Aldeyra Therapeutics announced that its 0.25% Reproxalap eye drops successfully achieved the primary endpoint in the second Phase III clinical trial for dry eye disease, marking a key advance in the treatment of dry eye disease. Dry eye is a complex and chronic eye disease that is often accompanied by multiple symptoms such as eye discomfort, visual impairment, and tear film instability. In severe cases, it may even cause vision loss. Therefore, it is of great clinical significance to find effective and safe treatments.

Dry Eye Disease (DED) is usually caused by inflammation of the eye, and the disease course is slow and recurring. Existing treatments include artificial tears, anti-inflammatory drugs, immunomodulators, etc. Among them, the only anti-inflammatory drug approved by the U.S. FDA for the treatment of dry eye is cyclosporine 0.05% cyclosporine ophthalmic emulsion and 5%Lifitegrast (Lifitegrast, trade nameXiidra). Ritalast is the only drug approved to target both the symptoms and signs of dry eye syndrome, but there are still issues with poor patient experience and limited efficacy. ReproxalapAs a new small molecule active aldehyde inhibitor, it has potential "first-in-class" properties. It can covalently bind to active aldehydes related to eye inflammation, block its damaging effect on proteins, reduce inflammatory reactions, and thereby improve dry eye symptoms.

This clinical trial was a randomized, double-blind, excipient-controlled design, and a total of 116 patients with dry eye syndrome were included in the trial. They were divided into a treatment group and a placebo group that received 0.25% Reproxalap . The results showed that within 80 to 100 minutes after eye drops, the ocular discomfort scores of patients who received Reproxalap were significantly lower than those of the control group, reaching the primary endpoint. In terms of safety, 0.25% Reproxalap showed good tolerability, with mild side effects and mostly temporary eye discomfort. No patient interrupted treatment due to adverse reactions, which provides a good basis for the clinical application of this drug.

Aldeyra TherapeuticsPresident andCEO Dr. Todd C. Bradysaid that based on current clinical data, Reproxalap has shown obvious advantages in reducing the ocular symptoms of dry eye disease, and has strong statistical significance. The company expects this data to respond to the FDA's previous feedback on the application materials, and looks forward to further communication with the regulatory agency. Although the FDA requires at least one additional fully controlled clinical study to further confirm the efficacy, Reproxalap has demonstrated relatively solid therapeutic potential. The company plans to include the latest data in the resubmission of its new drug application (NDA) in mid-2025 to help bring this innovative drug to patients faster.

Overall, 0.25% Reproxalap Eye Drops, as a new type of anti-inflammatory treatment drug, is expected to bring more effective treatment options to dry eye patients with its unique mechanism of action and good safety. With the continuous accumulation of clinical data in the future, Reproxalap may become an important breakthrough in the field of dry eye disease, relieving patients' long-term symptoms and improving their quality of life.

References:Aldeyra Therapeutics achieves primary endpoint in phase 3 dry eye disease chamber trial of reproxalap and plans NDA resubmission. News release. Aldeyra Therapeutics. May 5, 2025.